Skip to main content

ATF2 Antibody

Novus Biologicals, part of Bio-Techne | Catalog # NB100-835

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NB100-835

Key Product Details

Species Reactivity

Validated:

Human

Predicted:

Bovine (100%), Canine (100%), Rat (100%). Backed by our 100% Guarantee.

Applications

Peptide ELISA, Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Goat IgG

Concentration

0.5 mg/ml

Product Specifications

Immunogen

Peptide with sequence C-IVMAPSSQSQPSGS corresponding to C-Terminus according to NP_001871.2.

Localization

Nuclear

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Scientific Data Images for ATF2 Antibody

Western Blot: ATF2 Antibody [NB100-835]

Western Blot: ATF2 Antibody [NB100-835]

Western Blot: ATF2 Antibody [NB100-835] - Human primary astrocyte lysates probed with ATF2 antibody. WB image submitted by a verified customer review.
Western Blot: ATF2 Antibody [NB100-835]

Western Blot: ATF2 Antibody [NB100-835]

Western Blot: ATF2 Antibody [NB100-835] - Staining of HepG2 (A), K562 (B) and HeLa (C) nuclear lysates (35 ug protein in RIPA buffer). Antibody at 1 ug/mL. Detected by chemiluminescence.

Applications for ATF2 Antibody

Application
Recommended Usage

Peptide ELISA

Detection limit 1:32000

Western Blot

0.3 - 1 ug/mL
Application Notes
WB: Approx. 55 kDa band and 30 kDa band bands observed in lysates of human placenta. These bands correspond to earlier findings in scientific literature (PMID: 11932306). Approx. 75 kDa band observed in nuclear lysates of HeLa, HepG2 and K562 is reported in scientific literature (PMID: 19331149).

Reviewed Applications

Read 1 review rated 4 using NB100-835 in the following applications:

Formulation, Preparation, and Storage

Purification

Immunogen affinity purified

Formulation

Tris saline (20 mM Tris pH 7.3, 150 mM NaCl), 0.5% BSA

Preservative

0.02% Sodium Azide

Concentration

0.5 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at -20C. Avoid freeze-thaw cycles.

Background: ATF2

ATF2 (Activating Transcription Factor 2, CREBP, HB16, CREB2, TREB7) is a member of the ATF/CREB family of basic region leucine zipper DNA binding proteins that regulates transcription by binding to a consensus cAMP response element (CRE) in the promoter of various viral and cellular genes. Many of these genes are important in cell growth and differentiation, and in stress and immune responses. ATF2 is a nuclear protein that binds DNA as a dimer and can form dimers with members of the ATF/CREB and Jun/Fos families. It is a stronger activator as a heterodimer with cJun than as a homodimer. Several isoforms of ATF2 arise by differential splicing. The stable native full length ATF2 is transcriptionally inactive as a result of an inhibitory direct intramolecular interaction of its carboxy terminal DNA binding domain with the amino terminal transactivation domain. Following dimerization ATF2 becomes a short lived protein that undergoes ubiquitination and proteolysis, seemingly in a protein phosphatase-dependent mechanism. Stimulation of the transcriptional activity of ATF2 occurs following cellular stress induced by several genotoxic agents, inflammatory cytokines, and UV irradiation. This activation requires phosphorylation of two threonine residues in ATF2 by both JNK/SAP kinase and p38 MAP kinase. ATF2 is abundantly expressed in brain.

Long Name

Activating Transcription Factor 2

Alternate Names

CRE-BP1, CREB2, HB16, mXBP, TREB7

Entrez Gene IDs

1386 (Human); 81647 (Rat)

Gene Symbol

ATF2

Additional ATF2 Products

Product Documents for ATF2 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for ATF2 Antibody

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...